Recently, PAGly has been proposed to target β2-adrenergic receptors (β2-AR), offering potential benefits for cerebral ischemia/reperfusion injury through the inhibition of receptor signaling [50]. The gene discussed is ADRB2; the disease is Cerebral ischemia.